secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001140361-22-041132
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis enters gene editing collaboration with Metagenomi; raises FY2022 expense guidance
--------------------------------------------------------------------------------

- Upfront $80M payment to Metagenomi for exclusive worldwide rights to develop gene editing medicines for up to 8 targets.
- Collaboration covers 4 initial targets selected by Ionis, plus 4 more upon milestones; Metagenomi has co-development option.
- FY2022 guidance: OpEx raised to $900-925M (from $825-850M); net loss on non-GAAP now <$350M (from <$275M); revenue >$575M unchanged.
- Cash, cash equivalents and short-term investments ~$2.0B, unchanged.
- Each party agreed to exclusivity on selected targets for specified periods under the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036122041132/0001140361-22-041132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036122041132/brhc10044032_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-041132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer